Dr Vishnu walks through which of the two obesity drugs led to more weight loss, pointing to the head-to-head SURMOUNT-5 trial results.
Recap by typeshit. Post by @dr_vishnu_endocrinologist on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Patients who got Revita after stopping tirzepatide regained 5.1% of body weight versus 8.2% on sham, yet Fractyl shares fell as investors judged the benefit small.
New research points to a possible link between GLP-1 medications and changes in nails, and doctors weigh in on what so-called Ozempic nails could mean.
Loading…